Inhibition of CD26/DPP-IV enhances donor muscle cell engraftment and stimulates sustained donor cell proliferation by Parker, Maura H et al.
RESEARCH Open Access
Inhibition of CD26/DPP-IV enhances donor
muscle cell engraftment and stimulates sustained
donor cell proliferation
Maura H Parker
1*, Carol Loretz
1, Ashlee E Tyler
2, Lauren Snider
2, Rainer Storb
1,3 and Stephen J Tapscott
2,4*
Abstract
Background: Transplantation of myogenic stem cells possesses great potential for long-term repair of dystrophic
muscle. In murine-to-murine transplantation experiments, CXCR4 expression marks a population of adult murine
satellite cells with robust engraftment potential in mdx mice, and CXCR4-positive murine muscle-derived SP cells
home more effectively to dystrophic muscle after intra-arterial delivery in mdx
5cv mice. Together, these data
suggest that CXCR4 plays an important role in donor cell engraftment. Therefore, we sought to translate these
results to a clinically relevant canine-to-canine allogeneic transplant model for Duchenne muscular dystrophy
(DMD) and determine if CXCR4 is important for donor cell engraftment.
Methods: In this study, we used a canine-to-murine xenotransplantation model to quantitatively compare canine
muscle cell engraftment, and test the most effective cell population and modulating factor in a canine model of
DMD using allogeneic transplantation experiments.
Results: We show that CXCR4 expressing cells are important for donor muscle cell engraftment, yet FACS sorted
CXCR4-positive cells display decreased engraftment efficiency. However, diprotin A, a positive modulator of CXCR4-
SDF-1 binding, significantly enhanced engraftment and stimulated sustained proliferation of donor cells in vivo.
Furthermore, the canine-to-murine xenotransplantation model accurately predicted results in canine-to-canine
muscle cell transplantation.
Conclusions: Therefore, these results establish the efficacy of diprotin A in stimulating muscle cell engraftment,
and highlight the pre-clinical utility of a xenotransplantation model in assessing the relative efficacy of muscle stem
cell populations.
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Background
Duchenne muscular dystrophy (DMD), the most com-
mon and severe form of muscular dystrophy, is caused
by mutations in the dystrophin gene, the largest gene
identified in the human genome. Transplantation of
myogenic stem cells possesses great potential for long-
term repair of dystrophic muscle. Indeed, intramuscular
injection of adult satellite cell-derived myoblasts from a
normal syngeneic donor into mdx mice results in the
formation of dystrophin-positive muscle fibers [1-3].
However, in small-scale human clinical trials, intramus-
cular injection of donor myoblasts resulted in transient
expression of dystrophin in a small number of recipient
muscle fibers and triggered cellular immune responses
that destroyed newly-formed donor myotubes [4-8].
We used a clinically acceptable regimen of hematopoie-
tic stem cell transplantation to establish mixed donor/host
blood cell chimerism and immune tolerance in a canine
model of Duchenne muscular dystrophy (cxmd) [9]. Intra-
muscular injection of donor muscle-derived cells into chi-
meric cxmd recipients restored dystrophin expression for
at least 24 weeks in the absence of post-transplant
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may be a viable therapeutic option for muscular dystrophy.
Yet, it remains unclear from murine transplantation
experiments which cell population most effectively
engrafts into diseased skeletal muscle.
Embryonic myogenic progenitor cells express CXCR4,
G-protein coupled cell surface receptor, and migrate
towards regions of SDF-1 expression during limb muscle
development, suggesting that CXCR4/SDF-1 plays a role
in muscle cell homing. Indeed, CXCR4-positive muscle-
derived side population (SP) cells home more effectively to
dystrophic muscle after intra-arterial delivery in mdx
5cv
mice [10]. Moreover, CXCR4 expression marks a popula-
tion of adult satellite cells with robust engraftment poten-
tial in mdx mice [11]. Together, these data suggest that
CXCR4 plays an important role in donor cell engraftment.
We used the xenotransplant model to show that CXCR4
expression on canine donor muscle cells is also important
for cell engraftment, but FACS sorting for CXCR4-positive
cells decreased their engraftment efficiency. Diprotin A sti-
mulation of CXCR4, however, significantly increased the
number of canine dystrophin-positive muscle fibers and
canine-derived satellite cells by enhancing donor cell prolif-
eration. Moreover, xenotransplantation accurately predicted
results in canine-to-canine allogeneic transplantation
experiments, an important pre-clinical model for future
human clinical trials.
Methods
Canine donor cell isolation
The Institutional Animal Care and Use Committee at the
Fred Hutchinson Cancer Research Center, which is fully
accredited by the Association for Assessment and Accredi-
tation of Laboratory Animal Care, approved this study.
The biceps femoris muscle of a wild-type canine was biop-
sied as a survival surgery, and the biopsy was first digested
with 200 U/ml collagenase type 4 (Worthington Biochem-
ical, Lakewood, NJ, USA) in Dulbecco’s Modified Eagle
Medium (DMEM; Invitrogen, Carlsbad, CA, USA) supple-
mented with 5 mM CaCl2, 1 U/ml dispase (Invitrogen),
and 0.5% BSA for 30 min at 37°C. The intact fibers and
muscle pieces were rinsed in Hank’s Balanced Salt Solu-
tion (HBSS; Invitrogen) and transferred to 400 U/ml col-
lagenase type I (Sigma-Aldrich, St. Louis, MO, USA) in
DMEM (Invitrogen) supplemented with 5 mM CaCl2 for
45 min at 37°C. The digested muscle was triturated and
filtered through a series of nylon mesh filters, and the
resulting mononuclear cells washed twice in phosphate
buffered saline (PBS), and resuspended in PBS.
FACS
Anti-CXCR4 was obtained from R & D Systems (clone
44716; Minneapolis, MN, USA) and used at 10 μg/ml for
FACS sorting of 4-6 × 10
6 cells. PE-labeled anti-mouse
IgG2b was obtained from SouthernBiotech (Birmingham,
AL, USA) and used at 0.25 μg/ml. Freshly isolated canine
skeletal muscle cells were resuspended in FACS buffer
(Hanks Balanced Salt Solution [HBSS], 5% FBS) and
incubated on ice with anti-CXCR4 or isotype control, fol-
lowed by PE-labeled anti-mouse IgG. The cells were
washed and resuspended in FACS buffer containing 1 μl
o f5m MS Y T O X
® Blue (Invitrogen). The cells were
sorted using a BD Aria II, and the population of CXCR4-
positive:SYTOX blue-negative cells were collected and
prepared for injection.
Cell injection into mice and tissue processing
The right hindlimb of each 7 to 12-week-old NOD/SCID
mouse was exposed to 12 Gy of ionizing irradiation (Mark
1 cesium source, Sheppard and Associates, San Francisco,
CA, USA), and the tibialis anterior (TA) muscle of the
same hindlimb was injected with 50 μlo f1 . 2 %b a r i u m
chloride immediately after irradiation. The following day,
the same TA muscle was injected with 50 μl of canine
cells along the length of the muscle, so as to distribute
cells from the distal to the proximal end of the muscle.
Where noted, mice were administered 100 μg EdU intra-
peritoneally daily for 7 days. Injected muscle was harvested
28 days after injection unless otherwise indicated. Har-
vested mouse muscle was covered in OCT within a plastic
cryomold and placed on top of an aluminum block
immersed in liquid nitrogen. Cryosections were cut (8 to
10 μm) from the distal to the proximal end of the frozen
muscle using a Leica CM1850 cryostat, and adhered to
Superfrost slides (Fisher Scientific, Pittsburgh, PA, USA).
Each glass slide consisted of four serial sections, and the
corresponding section on the subsequent slide represented
a separation of approximately 200 μmf r o mt h ep r e v i o u s
slide.
Each TA muscle normally generated 24 slides, each con-
sisting of four serial sections. Initially, slides 6, 12, and 18
were stained for dystrophin and lamin A/C to determine
the region of highest engraftment. Three more even-num-
bered slides were chosen from the region of highest
engraftment and stained for canine dystrophin and lamin
A/C. Three odd-numbered slides in the same region were
used for Pax7 and lamin A/C co-staining. In almost all
cases, the region of highest engraftment was between
slides 6 and 18, representing the belly of the muscle,
which does not vary considerably in cross-sectional area.
Immunostaining
Primary antibodies specific for dystrophin were used at a
1:50 dilution, and included MANDYS107 (4H8), and
MANEX1A (4C7), developed by Glenn Morris and
obtained from the Developmental Studies Hybridoma
Bank developed under the auspices of the NICHD and
maintained by The University of Iowa, Department of
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(clone 636) was used at 1:100 and was obtained from
Vector Laboratories (Burlingame, CA, USA). Alexa fluor
488-conjugated goat anti-mouse IgG and Alexa fluor
568-conjugated goat anti-mouse IgG2b secondary antibo-
dies, both from Invitrogen, were used at 1:200. For dys-
trophin and lamin A/C staining, the sections were fixed
in acetone at -20°C for 10 min, allowed to dry, and rehy-
drated in PBS. Sections were blocked in 1× PBS buffer
containing 2% goat serum, 1% BSA, 0.1% cold fish skin
gelatin, and 0.05% sodium azide, followed by incubation
with primary antibody diluted in 1× PBS containing 1%
BSA, 0.1% cold fish skin gelatin, and 0.05% sodium azide.
Where appropriate, EdU was visualized using the Click-
iT EdU Alexa Fluor 647 Imaging kit according to the
manufacturer’si n s t r u c t i o n s( I n v i t r o g e n ) .T h es e c t i o n s
were incubated with secondary antibody diluted in 1×
PBS and mounted with ProLong Gold Anti-fade with
DAPI (Invitrogen).
Primary antibody specific for Pax7 antibody was used at
1:10, and was obtained from the Developmental Studies
Hybridoma Bank. Rabbit polyclonal antibody to laminin
was obtained from Abcam and used at 1:100. Alexa fluor-
conjuagted goat anti-mouse IgG1 (Pax7), Alexa fluor 568-
conjugated goat anti-mouse IgG2b (lamin A/C), and
Marina blue-conjugated goat anti-rabbit (laminin) were
used at 1:200, and obtained from Invitrogen. For Pax7,
laminin, and lamin A/C co-staining, cryosections were
fixed in 4% paraformaldehyde for 20 min at room tem-
perature, washed with 1× PBS, followed by permeabiliza-
tion with methanol at -20°C for 6 min. The sections were
washed in 1× PBS, and antigen retrieval was performed by
incubating the slides twice in 10 mM citric acid (pH 6.0)
at 90°C for 5 min. Sections were blocked and stained as
described above.
Photomicrographs were taken using either a Nikon E800
and a CoolSnap HQ camera, or a Zeiss AxioImager.Z1 as
part of a TissueFaxs system (TissueGnostics, Los Angeles,
CA, USA). The images for each field of view were stitched
together to form an entire cross-sectional view. Counts of
fibers expressing canine dystrophin, nuclei expressing
canine lamin A/C, and nuclei co-expressing Pax7 and
canine lamin A/C were done manually, and curve fitting
was performed using Microsoft Excel.
Primary myoblast culture and immunocytochemistry
Canine muscle and mouse muscle injected with canine
cells were chopped in 400 U/ml collagenase type I
(Sigma-Aldrich, St Louis, MO, USA) in DMEM and incu-
bated at 37°C for 45 min. The mixture was triturated and
filtered using a series of nylon mesh filters. The resulting
cells were cultured in growth medium (Ham’s F10, 20%
FBS, penicillin/streptomycin, 2.5 ng/ml bFGF). Once
confluence was reached, cultured cells were fixed in 4%
paraformaldehyde, and permeabilized with 0.3% Triton
X-100 in 1× PBS. Primary antibodies specific for Pax7
and myogenin (F5D) were obtained from the Develop-
mental Studies Hybridoma Bank. Cells were blocked in
10% goat serum, and incubated with primary antibody
diluted 1× PBS containing 1% BSA, 0.1% cold fish skin
gelatin, 0.05% sodium azide, 1× PBS. The cells were
washed in 1× PBS, incubated with secondary antibody
and mounted with ProLong Gold Anti-fade with DAPI
(Invitrogen). Photomicrographs were taken using a
Nikon E800 and CoolSnap HQ camera.
RNA isolation and RT-PCR
RNA was isolated using the RNeasy Kit (Qiagen, Valencia,
CA, USA) and 250 ng reverse transcribed using Super-
Script III (Invitrogen) and random primers. PCR was per-
formed using PlatinumTaq (Invitrogen) and one-tenth of
the reaction mix for 30 cycles with the following primers:
MyoD F1-CGATTCGCTACATCGAAGGT, MyoD R1-
AGGTGCCATCGTAGCAGTTC; CD26/DPP IV F1-G
TGTCTCCCGATGGACAGTT, CD26/DPP IV R1-CC
CGTTCCATGTGATTCTCT; SDF-1 F1-CAGCCT-
GAGCTACAGATGTCC, SDF-1 R1-CTTCAATTTCGG
GTCAATGC; CXCR4 F1-GAGCTCCATATATACCCT
TCAGAT A, CXCR4 R1-GGTAACCCATGACCAG-
GATG; Pax7 F1-AAGATTCTCTGCCGCTAC CA, Pax7
R1-TCACAGTGTCCGTCCTTCAG; RNA Polymerase
F1-CGCTGTGTCTGCTTCTTCTGC, RNA Polymerase
R1-TTGCCCTTGCACAGGTCATA; b-Actin F1-ACTGG
GACGACATGGAGAAG, b-Actin R1-GACAGCA-
CAGCCTGGATGG. PCR products were run on a 2%
agarose gel containing ethidium bromide and visualized
using a Gel Doc ™ system (BioRad, Hercules, CA, USA).
Hematopoietic cell transplantation (HCT)
Mixed breed cxmd canines were maintained as a col-
ony at the Fred Hutchinson Cancer Research Center,
as previously described [12]. Littermates composed of
healthy wild-type donors and cxmd recipient dogs were
matched by intrafamilial histocompatibility typing, and
the HCT protocol for cxmd canines was described pre-
v i o u s l y[ 9 ] .B r i e f l y ,o nD a y0t h ecxmd recipient
received 200 cGy TBI at a single dose delivered at 7
cGy/min from a linear accelerator (Varian CLINAC 4,
Palo Alto, CA, USA). Within 4 h of TBI, donor bone
marrow cells were infused intravenously. On Day 1,
freshly isolated donor G-PBMCs were infused intrave-
nously into the cxmd recipient. Postgrafting immuno-
suppression consisted of oral cyclosporine (CSP), 10
mg/kg twice daily, from Days 1 to 35, and 5 mg/kg
( M M F )f r o mD a y s0t o7 ,a n d7 . 5m g / k gM M Ff r o m
Days 8 to 28. All dogs were given standard supportive
care that included subcutaneous fluids with electro-
lytes, and systemic antibiotics.
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A muscle biopsy was obtained from the hematopoietic
stem cell donor, and muscle-derived cells were isolated
as described above for canine-to-murine transplantation
experiments. The biceps femoris (BF) muscle of the
cxmd recipient was marked with non-dissolvable sutures
to identify six sites of cell injection. Each suture site was
transplanted with donor muscle-derived cells, involving
six injections surrounding each suture.
One site from each BF muscle was biopsied 8, 16, and
24 weeks after injection and frozen in OCT (Tissue-Tek,
Torrance, CA, USA). Cryosections (8 to 10 μm) were
adhered to Superfrost slides (Fisher Scientific), fixed in
acetone at -20°C for 10 min, allowed to dry, and rehy-
drated in PBS. Primary and secondary antibodies used
for dystrophin staining, and the method were described
above.
Results
Canine cells engraft into regenerating mouse muscle
The lower right hindlimb of each NOD/SCID mouse
was exposed to 12 Gy of ionizing radiation, the lowest
dose that prevented host muscle regeneration (data not
shown). The tibialis anterior (TA) muscle of the same
hindlimb was injected with barium chloride to induce
muscle regeneration, and the following day, mononuc-
lear cells isolated from a wild-type canine muscle biopsy
were injected directly into the same TA muscle, along
the length of the muscle, from the proximal to the distal
end. The injected muscle was harvested 28 days after
injection, and cryosections were immunostained using
antibodies specific for canine dystrophin and canine
lamin A/C. Muscle injected with 1 × 10
4 (Figure 1A a
and 1b) or 4 × 10
4 (Figure 1A c and 1d) canine cells
displayed a significant number of nuclei expressing
canine lamin A/C (Figure 1A a and 1c) and fibers
expressing canine dystrophin (Figure 1A b and 1d), indi-
cating canine donor cell engraftment.
Canine donor cell engraftment is quantifiable and
consistent
NOD/SCID mice were injected as described above, with
freshly isolated canine muscle-derived mononuclear cells
from three different donor dogs, with cell doses ranging
from 2 × 10
3 to 5 × 10
4 cells per injection. The number of
fibers expressing canine dystrophin and the number of
nuclei expressing canine lamin A/C per cross-section
of muscle were determined using a minimum of three
cross-sections from each injected muscle, from within the
region of highest engraftment and covering a distance of
approximately 800 to 1200 μm. Muscles from at least two
separate experiments were analyzed; each experiment
representing a single canine muscle biopsy and cell pre-
paration, and a minimum of three mice for each cell dose.
Initially, we expressed canine donor cell engraftment as
a percentage of total fibers expressing canine dystrophin
or a percentage of total nuclei expressing canine lamin
A/C. However, the amount of host mouse muscle remain-
ing after BaCl2 induced degeneration was not consistent
between recipients, resulting in variable values when
expressing engraftment as a percentage. However, there
was a reproducible positive correlation between the num-
ber of cells injected from canine donor G982 and the
number of fibers expressing canine dystrophin per cross-
section (Figure 1B) and the number of nuclei expressing
canine lamin A/C per cross-section (Figure 1C). The cor-
relation between cell dose and engraftment was also
observed for canine donors G993 and H299 (Additional
file 1). A logarithmic curve was determined to be the best
fit curve for the data shown in Figures 1B and 1C, and S1
as the r
2 value was more than 0.95 for all curves shown.
Moreover, a linear relationship between the number of
donor nuclei, as determined by expression of canine lamin
A/C, and the number of fibers expressing canine dystro-
phin, was seen for all donors, with an average of approxi-
mately 1.75 ± 0.07 canine nuclei per myofiber expressing
canine dystrophin per cross-section (Figure 1D, Additional
file 1).
Notably, each donor’s muscle-derived cell population
had a different capacity for reconstitution as measured by
the number of fibers expressing canine dystrophin, the
number of nuclei expressing canine lamin A/C, and the
number of nuclei expressing Pax7 and canine lamin A/C.
Yet, different muscle cell preparations from the same
donor displayed similar levels of engraftment (Figures 1B
and 1C, Additional file 1). Therefore, the canine-to-murine
xenotransplantation model provides a sufficiently robust
platform to quantitatively assess engraftment potential of
different populations of canine muscle cells.
Canine donor cells consistently engraft to the murine
satellite cell niche
Nuclei expressing Pax7 and canine lamin A/C were
detected at the outer periphery of muscle fibers and
underneath laminin of the extracellular matrix, suggest-
ing that canine cells had engrafted into the niche nor-
mally occupied by murine satellite cells (Figure 2A). In
addition, a small number of Pax7-positive nuclei not
expressing lamin A/C were detected, indicating that irra-
diated and injected muscles maintained a minimal popu-
lation of murine satellite cells (data not shown).
Importantly, the number of canine-derived Pax7-positive
cells increased with the number of donor cells injected,
and engraftment at all cell doses was consistent for each
donor (Figure 2B, data not shown).
To confirm that mononuclear cells expressing canine
lamin A/C present in transplanted muscle were main-
tained in the myogenic lineage, mouse TA muscles
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Page 4 of 16Figure 1 Canine muscle cell engraftment into mouse muscle is quantifiable and consistent. (A) Cryosections from NOD/SCID mouse
muscle injected with 1 × 10
4 (a, b) or 4 × 10
4 (c, d) canine muscle-derived mononuclear cells were immunostained with anti-lamin A/C (a, c),
or anti-dystrophin (MANDYS107 - b, d) and fluorescently labeled secondary antibodies. (B, C) Cryosections from mouse muscle injected with
canine muscle-derived mononuclear cells were immunostained with anti-lamin A/C or anti-dystrophin (MANDYS107), and fluorescently labeled
secondary antibodies. The number of fibers expressing canine dystrophin (B) and the number of nuclei expressing canine lamin A/C (C) per
cross-section were counted using cryosections surrounding the region of highest engraftment within the muscle. The points on the graphs
represent the average of the averages ± SD, where the average was calculated from three cryosections per mouse, and the average of the
averages was calculated from at least three mice per cell dose, and at least two separate cell isolations per cell dose. (D) The number of nuclei
expressing canine lamin A/C was plotted as a function of the number of fibers expressing canine dystrophin per cross-section.
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digested with collagenase, and the resulting mononuclear
cells were cultured in growth medium containing 20%
fetal bovine serum and 2.5 ng/ml bFGF for 7 to 10 days.
Cells were fixed and stained for expression of canine
lamin A/C to detect cells of donor canine origin, and for
Pax7 and myogenin to detect all myogenic cells. We
chose to stain cells for expression of both Pax7 and myo-
genin to include both undifferentiated and differentiated
muscle cells. Cells expressing Pax7 or myogenin isolated
and cultured from muscle injected with 2,000 or 10,000
canine donor cells were exclusively canine lamin A/C-
positive, indicating that a subpopulation of transplanted
canine cells was capable of generating mononuclear mus-
cle cells in vitro (Figure 2C). Muscles injected with 400
canine donor cells did not yield detectable numbers of
canine muscle cells in vitro, perhaps due to the small
number of donor cells engrafted.
Figure 2 Canine derived Pax7-positive cells persist in injected mouse muscle. (A) Cryosections from mouse muscle injected with canine
muscle-derived mononuclear cells were immunostained with anti-Pax7 (green), anti-lamin A/C (red), and anti-laminin (blue). (B) The number of
nuclei expressing canine lamin A/C and Pax7 per cross-section was counted, and the points on the graph represent the average of the averages
± SD, where the average was calculated from three cryosections per mouse, and the average of the averages was calculated from at least three
mice per cell dose, and at least two separate cell isolations per cell dose. (C) Satellite cell-derived myoblasts were isolated and cultured from
canine muscle, and mouse muscle injected with 400, 2000, or 10,000 canine muscle-derived mononuclear cells. The cells were fixed and
immunostained with anti-lamin A/C (red), and anti-Pax7 and anti-myogenin (both green).
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CXCR4
Recently, a subpopulation of satellite cells expressing
CXCR4 have been identified in mice, and cells sorted for
expression of CXCR4 and b1-integrin efficiently engraft
into regenerating muscle of mdx mice [11,13]. We
detected expression of CXCR4 transcript in cultured pro-
liferating and differentiating canine satellite cell derived
myoblasts, and the freshly isolated population of mixed
canine muscle-derived cells (Figure 3A). SDF-1, the sole
ligand for CXCR4, was detected in RNA from whole
canine skeletal muscle and the freshly isolated population
of mixed canine muscle-derived cells, but not cultured
myoblasts, suggesting that satellite cells or another popula-
tion of cells were the source of SDF-1. Notably, Pax7 tran-
script, but not MyoD transcript, was present in freshly
isolated muscle-derived cells, indicating that this popula-
tion of cells has a more progenitor-like phenotype and has
not initiated myogenic commitment and differentiation.
FACS sorting of cultured canine proliferating primary
myoblasts demonstrated that 98.5% of viable cells were
CXCR4-positive, whereas 88% of viable cells were b1-
integrin-positive (data not shown). We sorted freshly iso-
lated canine muscle-derived cells from various donors and
observed that approximately 1 to 3.5% of canine muscle-
derived mononuclear cells were CXCR4-positive, and less
than 0.5% of cells were CD45-positive; however, we were
unable to detect a significant population of b1-integrin-
positive cells (Figure 3B, data not shown).
Sorting for CXCR4-positive cells does not increase
engraftment efficiency
NOD/SCID mice were injected with freshly isolated mixed
canine muscle-derived cells and CXCR4-positive cells
sorted from the mixed cell population. Injection of 1 × 10
4
CXCR4-positive sorted cells resulted in a greater number
of fibers expressing canine dystrophin (Figure 3D), nuclei
expressing canine lamin A/C (Figure 3E), and Pax7/canine
lamin A/C double-positive nuclei (Figure 3F) per cross-
section of muscle when compared to injection of 1x10
4
mixed cells. However, for this experiment, 1% of the par-
ent population of mixed cells was CXCR4-positive, and as
such, 1 × 10
6 mixed cells were required to obtain 1 × 10
4
CXCR4-positive sorted cells. Therefore, the true compari-
son is 1 × 10
4 mixed cells to 100 sorted cells, and 5 × 10
4
mixed cells to 500 sorted cells. Using this relationship, the
freshly isolated mixed canine muscle-derived cells resulted
in a greater number of fibers expressing canine dystrophin
(Figure 3D), nuclei expressing canine lamin A/C (Figure
3E), and nuclei expressing both Pax7 and canine lamin
A/C (Figure 3F).
Recombining CXCR4-positive and CXCR4-negative
cells after sorting did not restore engraftment to the
level observed with the mixed cell population (data not
shown). Moreover, depleting the parent mixed canine
muscle-derived cell population of CXCR4-expressing
cells also resulted in a 10-fold decrease in the ability to
generate fibers expressing canine dystrophin within reci-
pient mouse muscle (Figure3 G ) ,i n d i c a t i n gt h a tt h e
CXCR4-positive cells within the mixed cell population
are likely responsible for the majority of the observed
engraftment, and that sorting may have a negative effect
on cell engraftment.
CXCR4 and SDF-1 play an important role in donor cell
engraftment
The process of sorting cells may adversely affect engraft-
ment by reducing cell viability; however, it is also possible
that binding of the antibody to the cell surface CXCR4
receptor interferes with function. Muscle injected with
freshly isolated mixed canine muscle-derived cells incu-
bated with a-CXCR4 antibody, but not subjected to
FACS, displayed significantly fewer myofibers expressing
canine dystrophin (Figure 4A), fewer nuclei expressing
canine lamin A/C (Figure 4B), and fewer nuclei expressing
Pax7 and canine lamin A/C (Figure 4C) than muscle
injected with cells alone or cells incubated with control
antibody. This may be due to antibody-mediated internali-
zation of the receptor or blocking of SDF-1 binding to the
CXCR4 receptor [14-17]. Either mechanism argues for an
important role for CXCR4 in engraftment and/or differen-
tiation of donor cells.
The function of the CXCR4 receptor requires binding of
its ligand, SDF-1. We compared engraftment of the freshly
isolated mixed canine muscle-derived cells alone to mixed
cells incubated before injection with 10 ng/ml of SDF-1 or
1 0n g / m lo fF G F - 2 .S D F - 1 ,b u tn o tF G F - 2 ,s p e c i f i c a l l y
reduced the number of fibers expressing canine dystrophin
(Figure 4D), the number of nuclei expressing canine lamin
A/C (Figure 4E), and the number of nuclei expressing
Pax7 and canine lamin A/C (Figure 4F). Therefore, exo-
genously added SDF-1 did not improve donor cell engraft-
ment, and indeed, appeared to mimic the effect of the
anti-CXCR4 antibody. It is intriguing to hypothesize that
exogenous SDF-1 blocked binding of CXCR4 on canine
donor cells to SDF-1 in recipient mouse muscle.
Diprotin A treatment of donor cells enhances
engraftment through CXCR4
Binding of SDF-1 to CXCR4 is negatively regulated by
CD26/DPP-IV, a cell surface peptidase that cleaves SDF-
1 at the N-terminus [18,19]. CD26 is expressed on
hematopoietic stem cells, and inhibition of peptidase
activity with diprotin A enhances engraftment of donor
hematopoietic cells to the recipient bone marrow niche,
presumably by strengthening the interaction between
CXCR4 on the surface of donor stem cells and SDF-1
present in the bone marrow niche [20,21].
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Page 7 of 16Figure 3 Sorting for CXCR4-positive cells does not enhance engraftment. (A) RNA isolated from whole canine skeletal muscle (SkM),
proliferating canine satellite cell-derived myoblasts (PrMbs), differentiating myoblasts (DfMbs), and freshly isolated canine muscle-derived cells (F-
SkMCs), was reverse transcribed and amplified using primers for the genes indicated. (B) Canine muscle-derived mononuclear cells were
incubated with anti-CXCR4 and PE-labeled secondary antibody, or isotype control and PE-labeled secondary antibody, and SYTOX blue to label
dead cells, and sorted using FACS. The population of CXCR4-positive:SYTOX blue-negative cells indicated by the box were collected and
prepared for injection. (C) Cryosections from mouse muscle injected with 1 × 10
4 or 5 × 10
4 freshly isolated mixed canine muscle-derived
mononuclear cells, or 100, 500, or 1 × 10
4 CXCR4-positive sorted cells, were immunostained with anti-dystrophin (MANDYS107) or anti-lamin A/
C, and fluorescently labeled secondary antibody. (D, E, F) The number of fibers expressing canine dystrophin (D), the number of nuclei
expressing canine lamin A/C (E), and the number of nuclei expressing canine lamin A/C and Pax7 (F) per cross-section were determined. The
bars represent the average of the averages ± SD, where the average was calculated from three cryosections per mouse, and the average of the
averages was calculated from three mice per condition. (G) Cryosections from mouse muscle injected with 1 × 10
4 freshly isolated mixed canine
muscle-derived mononuclear cells, CXCR4-negative sorted cells, or CXCR4-positive sorted cells were immunostained with anti-dystrophin
(MANDYS107) and fluorescently labeled secondary antibody. The number of fibers expressing canine dystrophin per cross-section was
determined. The bars represent the average of the averages ± SD, where the average was calculated from three cryosections per mouse, and
the average of the averages was calculated from three mice per condition.
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Page 8 of 16RT-PCR demonstrated that cultured proliferating and
differentiating canine satellite cell derived myoblasts, and
the freshly isolated population of mixed muscle-derived
cells expressed CD26/DPP-IV transcript (Figure 3A).
Freshly isolated canine bone marrow cells, a positive con-
trol for CD26/DPP-IV activity, and muscle-derived cells
were incubated with Gly-Pro-p-nitroanilide, a substrate of
CD26/DPP-IV, and production of the cleavage product, p-
nitroaniline, was monitored by measuring absorbance at
405 nm. Muscle-derived mononuclear cells displayed
CD26/DPP-IV activity at a level comparable to canine
bone marrow cells, and this activity was inhibited with
diprotin A (Figure 5A).
Diprotin A treatment of donor cells before injection sig-
nificantly increased the number of fibers expressing canine
dystrophin (Figure 5B), the number of nuclei expressing
canine lamin A/C (Figure 5C), and the number of Pax7/
canine lamin A/C double-positive nuclei detected in
Figure 4 Anti-CXCR4 antibody and SDF-1 inhibit engraftment. ( A ,B ,C )Cryosections from mouse muscle injected with 1 × 10
4 freshly
isolated mixed canine muscle-derived mononuclear cells alone, cells pre-incubated with anti-CXCR4, cells pre-incubated with control antibody,
or CXCR4-positive sorted cells, were immunostained with anti-dystrophin (MANDYS107) or anti-lamin A/C, and fluorescently labeled secondary
antibody. The number of fibers expressing canine dystrophin (A), the number of nuclei expressing canine lamin A/C (B), and the number of
nuclei expressing canine lamin A/C and Pax7 (C) per cross-section were determined. The bars represent the average of the averages ± SD,
where the average was calculated from three cryosections per mouse, and the average of the averages was calculated from three mice per
condition. The P values are the result of a Student’s t-test. (D, E, F) Skeletal muscle cryosections from NOD/SCID mouse muscle injected with 1
×1 0
4 canine muscle-derived mononuclear cells alone, or cells incubated with 10 ng/ml SDF-1 or FGF-2 before injection, were immunostained
with anti-dystrophin (MANDYS107) or anti-lamin A/C, and fluorescently labeled secondary antibody. The number of fibers expressing canine
dystrophin (D), the number of nuclei expressing canine lamin A/C (E), and the number of nuclei expressing canine lamin A/C and Pax7 (F) per
cross-section were determined. The bars represent the average of the averages ± SD, where the average was calculated from three cryosections
per mouse, and the average of the averages was calculated from three mice per condition. The P values are the result of a Student’s t-test.
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Page 9 of 16injected muscle (Figure 5D). To confirm the increase in
donor nuclei present, a PCR-based assay that distinguishes
between canine and mouse DNA showed that mouse mus-
cle injected with diprotin A treated donor canine cells had
three-fold more canine DNA content than muscle injected
with cells alone (data not shown).
However, CD26/DPP-IV cleaves other chemokines,
such as IP-10/CXCL10 and MIP1b/CCL4 [22,23]. To
Figure 5 Diprotin A enhances engraftment of donor cells. (A) 1×1 0
5 canine bone marrow cells (BMC), and 1 × 10
5 freshly isolated skeletal
muscle-derived cells (SkMC) alone, or with 5 mM diprotin A (SkMC+dpA), were incubated with Gly-Pro-p-nitroaniline for 2 h. The nmol of p-
nitroaniline (pNA) produced by peptidase cleavage was determined by measuring absorbance at 405 nm and converting the value to nmol of
pNA using a standard curve. The bars represent the average nmol of pNA produced from three separate samples, and the P values are the result
of a Student’s t-test. (B, C, D) Cryosections from mouse muscle injected with 1 × 10
4 or 5 × 10
4 canine muscle-derived mononuclear cells alone
or cells treated with 5 mM diprotin A were probed with anti-dystrophin (MANDYS107), anti-lamin A/C, or anti-lamin A/C and anti-Pax7, and
fluorescently labeled secondary antibody. The number of fibers expressing canine dystrophin (B), the number of nuclei expressing canine lamin
A/C (C), and the number of nuclei expressing canine lamin A/C and Pax7 (D) per cross-section were determined. The bars represent the average
of the averages ± SD, where the average was calculated from three cryosections per mouse, and the average of the averages was calculated
from three mice per condition. The P values are the result of a Student’s t-test. (E, F) Cryosections from mouse muscle injected with 1 × 10
4
freshly isolated mixed canine muscle-derived mononuclear cells alone, cells treated with 5 mM diprotin A, or cells treated with 5 mM diprotin A
and a-CXCR4 antibody, were probed with anti-dystrophin (MANDYS107), or anti-lamin A/C, and fluorescently labeled secondary antibody. The
number of fibers expressing canine dystrophin (E) and the number of nuclei expressing canine lamin A/C (F) per cross-section were determined.
The bars represent the average of the averages ± SD, where the average was calculated from three cryosections per mouse, and the average of
the averages was calculated from three mice per condition. The P values are the result of a Student’s t-test.
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with diprotin A was specific for SDF-1/CXCR4, canine
muscle-derived cells were incubated with diprotin A
alone or with diprotin A and a-CXCR4 antibody before
injection. As shown in Figures 5E and 5F, the increase
in engraftment in the presence of diprotin A was pre-
vented by a-CXCR4 antibody, indicating that diprotin A
specifically affected binding of SDF-1 to CXCR4.
Diprotin A increases engraftment of donor derived
Pax7-positive cells
NOD/SCID mice were injected as described above with 1
×1 0
4 untreated freshly isolated mixed canine muscle-
derived cells, or 1 × 10
4 diprotin A treated cells, and
engraftment was measured weekly for 4 weeks (Figure 6A,
B, C), or at weeks 3, 5, and 7 after injection (Figure 6D, E,
F). Different donors were used for the experiment shown
in Figure 6A, B, Cand the experiment shown in Figure 6D,
E, F, which resulted in a different level of engraftment.
However, the trend in engraftment as a function of time,
and the effect of diprotin A is similar.
In muscle injected with untreated cells, the number of
canine dystrophin-positive fibers reached a plateau 3
weeks after injection, and remained constant from weeks
3t h r o u g h7( F i g u r e6 Aa n d6 D ) .I nc o n t r a s t ,m u s c l e
injected with diprotin A-treated cells displayed a continu-
ous increase in canine dystrophin-positive fibers for no
less than 7 weeks after donor cell injection, and beyond
week 3, displayed a significantly greater number of canine
dystrophin-positive fibers compared to muscle injected
with untreated cells (Figure 6A and 6D).
A similar pattern is observed for the number of nuclei
expressing canine lamin A/C per cross-section (Figure 6B
and 6E). However, the number of Pax7/canine lamin A/C
double-positive cells are significantly increased in muscle
injected with diprotin A-treated cells at all time points
(Figure 6C and 6F). Moreover, there is a significant
increase in the number of Pax7/canine lamin A/C double-
positive cells between weeks 1 and 2 in muscle injected
with diprotin A-treated cells, suggesting that Pax7/canine
lamin A/C double-positive cells proliferated in vivo.
Diprotin A maintains donor cell proliferation
To quantitatively assess proliferation of donor cells in
vivo, the nucleoside analog, EdU, was administered daily
for 7 days, during weeks 1, 2, 3, or 4 after injection of
untreated cells or diprotin A-treated cells into NOD/
SCID mice. During weeks 1 and 2, both EdU-positive
and EdU/canine lamin A/C double-positive nuclei were
observed; however, EdU-positive cells that did not co-
express canine lamin A/C were rare in weeks 3 and 4,
suggesting that proliferating cells present during weeks 3
and 4 were mainly donor-derived (data nor shown).
The proportion of EdU/canine lamin A/C double-posi-
tive cells decreased in muscle injected with untreated cells
and reached a plateau of approximately 10% by week 3
(Figure 6G). In contrast, diprotin A treatment of donor
cells resulted in an increase in the proportion of donor
cells incorporating EdU at weeks 3 and 4 after injection,
reaching approximately 25 to 30% of cells. Less than 1% of
cells co-expressed canine lamin A/C and caspase-3 at
weeks 1 and 4 after injection, and diprotin A treatment
did not affect the number of canine donor cells expressing
caspase-3 (data not shown). This is consistent with the
view that the majority of donor cell death occurs in the
first 24 h after injection [24,25]. Together, these data indi-
cate that diprotin A treatment maintained a greater pro-
portion of donor cells in proliferation.
The proportion of EdU/canine lamin A/C double-posi-
tive cells that also express Pax7 remained constant at
approximately 16% in muscle injected with untreated cells
(Figure 6H). In muscle injected with diprotin A-treated
cells, this proportion increased to 35% at week 3, and
remained significantly higher than in muscle injected with
untreated cells. This indicates that diprotin A treatment
maintains a greater proportion of proliferating donor
derived Pax7-positive myogenic cells in vivo.
Diprotin A enhances engraftment of donor cells in
immune tolerant cxmd canines
Together, these current data indicate that the most effec-
tive regimen involves intramuscular transplantation of a
freshly isolated mixed population of canine muscle-derived
cells treated with diprotin A before injection. Therefore, to
determine if these results can be translated to a large ani-
mal model of muscular dystrophy, we chose to compare
engraftment of freshly isolated mixed muscle-derived cells
alone to cells treated with diprotin A using the immune
tolerant cxmd canine model of DMD.
Two cxmd canines underwent hematopoietic stem cell
transplantation (HSCT), as previously described [9].
Briefly, each cxmd recipient was exposed to 200 cGy of
total body irradiation, and infused with bone marrow and
G-CSF mobilized peripheral blood mononuclear cells
from a DLA-identical littermate donor. For the first
cxmd recipient, H376, analysis of donor chimerism 4
weeks after transplant demonstrated that 80% of granulo-
cytes and 46% of lymphocytes were donor derived. How-
ever, 12 weeks after transplant, donor hematopoietic
chimerism increased to 99% for granulocytes and 80% for
lymphocytes and remained constant thereafter. The
donor muscle cell injection was performed 15 weeks after
bone marrow transplantation. A muscle biopsy was
obtained from the hematopoietic stem cell donor, and
muscle-derived cells were isolated as described above for
canine-to-murine transplantation experiments.
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Page 11 of 16Figure 6 Diprotin A enhances proliferation of donor cells in vivo. Mouse muscle injected with 1 × 10
4 canine muscle-derived mononuclear
cells alone, or cells treated with 5 mM diprotin A, were harvested weekly for 4 weeks after injection (A, B, C), or at 3, 5, or 7 weeks after
injection (D, E, F) and cryosections probed with anti-dystrophin (MANDYS107), anti-lamin A/C, and/or Pax7, and fluorescently labeled secondary
antibody. The number of fibers expressing canine dystrophin (A, D), and the number of nuclei expressing canine lamin A/C (B, E), and the
number of nuclei co-expressing Pax7 and canine lamin A/C (C, F) per cross-section were determined, and the points represent the average of
the averages ± SD, where the average was calculated from three cryosections per mouse, and the average of the averages was calculated from
three mice per condition. (G, H) Mice injected with 1 × 10
4 canine muscle-derived mononuclear cells alone, or cells treated with 5 mM diprotin
A, were given EdU daily for 1 week during weeks 1, 2, 3, or 4 after injection. Injected muscle was harvested after the last dose of EdU, and
cryosections stained for canine lamin A/C, or Pax7 and canine lamin A/C, and EdU. The percentage of canine lamin A/C-positive nuclei that
incorporated EdU (G) and the percentage of canine lamin A/C:Pax7 double positive nuclei that incorporated EdU (H) per cross-section were
determined. The points represent the average of the averages ± SD, where the average was calculated from three cryosections per mouse, and
the average of the averages was calculated from three mice per condition. The P value is the result of a Student’s t-test.
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cxmd recipient was marked with non-dissolvable sutures
to identify six sites of cell injection. In an attempt to
mimic the xenotransplant regimen, three sites were
injected with 5 × 10
5 cells resuspended in 1.2% barium
chloride, and three sites with 5 × 10
5 diprotin A-treated
cells resuspended in 1.2% barium chloride. The sites
injected with untreated cells were separated from the
sites injected with diprotin A-treated cells by a mini-
mum of 5 cm to prevent crossover or contamination.
Injected muscle was biopsied 8, 16, and 24 weeks after
injection. The average number of dystrophin-expressing
fibers per cross-section of muscle was determined using
five cryosections from each biopsy, covering a total dis-
tance of 1000 μm, and normalized to cross-sectional
area. Diprotin A treatment of donor cells resulted in a
dramatic 6.8-fold increase in the number of fibers
expressing dystrophin 24 weeks after injection, recapitu-
lating the effect observed in canine-to-murine xeno-
transplantation experiments (Figure 7A).
To determine if the active muscle regeneration induced
by barium chloride was important for donor cell engraft-
ment, a second chimeric cxmd recipient, H220, was
injected with cells resuspended in PBS alone. Analysis of
donor chimerism in H220 8 weeks after HSCT demon-
strated that 51% of granulocytes and 16% of lymphocytes
were donor derived. However, 12 weeks after transplant,
donor hematopoietic chimerism dropped to 3% and
remained constant thereafter. The donor muscle cell
injection was performed 37 weeks after HSCT. The
biceps femoris (BF) muscles on each side of the cxmd
recipient were marked with non-dissolvable sutures to
identify six sites of cell injection. The left BF muscle was
injected with 4 × 10
5 cells alone, and the right BF muscle
injected with 4 × 10
5 diprotin A-treated cells.
Biopsies of injected muscle were obtained 8, 16, and
24 weeks after injection. Diprotin A treatment of donor
cells resulted in a 2.6-fold increase in the number of dys-
trophin-positive fibers 24 weeks after injection (Figure 7B).
The number of dystrophin-positive fibers 24 weeks after
injection was 15.3 per mm
2 for H220 as compared to 90.3
per mm
2 for H376, suggesting that co-injection of cells
with barium chloride enhanced engraftment of donor
cells. Together, these data indicate that diprotin A success-
fully enhanced engraftment of donor cells to dystrophic
skeletal muscle, and that results from the xenotransplant
model accurately predicted results from the canine-to-
canine allogeneic model.
Discussion
Transplantation of myogenic stem cells possesses great
potential for long-term repair of dystrophic muscle. We
previously established an immune tolerant canine model
of muscular dystrophy using cxmd canines to test the
feasibility of allogeneic muscle cell transplantation, and
demonstrated that intramuscular injection of donor cells
restored expression of dystrophin for at least 24 weeks
in the absence of post-transplant immunosuppression.
This is an important pre-clinical model as the pheno-
type of the canine model of DMD (cxmd) faithfully reca-
pitulates the human disease, and is expected to respond
to therapeutic intervention in a way that is similar to
human dystrophic muscle. Indeed, these dogs have been
successfully used to test viral-mediated gene delivery
and anti-sense oligonucleotide induced exon skipping
approaches for restoring dystrophin function prior to
human clinical trials [26-31]. Specifically, studies of gene
therapy in cxmd canines revealed an unexpected
immune reaction not observed in mice, which appears
to be recapitulated in DMD patients [32].
However, the canine-to-murine xenotransplant model
is a more rapid and cost-effective means of quantitatively
comparing donor cell engraftment. Importantly, we show
that the canine-to-murine xenotransplant model accu-
rately predicted results of allogeneic transplantation
involving the cxmd canine model of muscular dystrophy.
Once we identify the most effective cell population,
canine-to-canine allogeneic transplantation will allow us
to address the problems of limited spread of donor cells
from the sites of injection, as well as dysregulation of sig-
nalling pathways that affect muscle regeneration. There-
fore, the xenotransplant model will prioritize the most
effective regimens and facilitate translation to the pre-
clinical immune tolerant cxmd canine model of DMD.
These data also suggest that a human-to-murine xeno-
transplant model will accurately predict results of donor
muscle cell transplantation in clinical trials. A number of
groups have successfully established human-to-murine
xenotransplant models, mainly using cultured human
myoblasts [33-37]. We will also generate a human-to-
murine xenotransplant model using freshly isolated mus-
cle cells, and translate the most effective canine regimens
to this model to confirm that equivalent human cell
populations engraft and respond as predicted by the
canine studies.
We used the canine-to-murine xenotransplant model
to clearly demonstrate that CXCR4 plays an important
role in canine donor cell engraftment, confirming results
observed in murine-to-murine transplantation studies
[10,11]. CXCR4 binds to its ligand, SDF-1, dimerizes, and
activates downstream kinases, including focal adhesion
kinase (FAK), which has been shown to regulate expres-
sion of caveolin-3 and b1-integrin, genes essential for
myoblast fusion [38-44]. Indeed, in vitro studies using
primary mouse myoblasts demonstrate that CXCR4/
SDF-1 is required for proper myogenic fusion, yet also
regulates migration of both proliferating and terminally
differentiated muscle cells [45].
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Page 13 of 16A role for CXCR4 in migration of muscle cells suggests
that CXCR4 binding to SDF-1 is involved in homing of
muscle cells to a niche. Studies in murine and avian sys-
tems have clearly shown that myogenic progenitor cells
express CXCR4 and migrate towards regions of SDF-1
expression during embryonic limb muscle development
[46,47]. Expression of SDF-1 and heparin sulfate proteo-
glycans (HSPGs) increases during the first 3 to 5 days after
induction of muscle regeneration, presumably functioning
to attract satellite cells and/or immune cells to the site of
damage, both of which are required for regeneration
[45,48,49]. We clearly show that diprotin A treatment of
donor cells resulted in an increased number of Pax7/
canine lamin A/C double-positive cells within injected
muscle, suggesting that diprotin A stimulated engraftment
of donor cells to a “niche” within regenerating muscle.
This is consistent with studies demonstrating that diprotin
A stimulates homing and adhesion of donor hematopoietic
stem cells (HSCs) to the bone marrow niche [21,50].
However, expression of Pax7 is not confined to quies-
cent satellite cells, and as such the number of Pax7/
canine lamin A/C double-positive cells may not accu-
rately measure the number of donor cells residing in the
host satellite cell niche, but rather measures the number
of donor derived myogenic mononuclear cells, either
quiescent or proliferating. Although this does not con-
tradict the hypothesis that diprotin A enhances donor
cell engraftment to a niche, it does suggest that diprotin
A may have improved donor cell survival after injection,
or induced donor cell proliferation in vivo. Indeed, the
proportion of Pax7/canine lamin A/C double-positive
cells that incorporate EdU is significantly higher in mus-
cle injected with diprotin A-treated cells, indicating a
role for diprotin A in stimulating donor cell
proliferation.
Currently, a clinical trial is underway at Indiana Uni-
versity School of Medicine using sitagliptin, a CD26/
DPP-IV inhibitor, to enhance engraftment of cord blood
stem cells in HSC transplant for patients with hematolo-
gical malignacies. Sitagliptin is FDA-approved for use in
patients to lower blood sugar levels, and as a DPP-IV
i n h i b i t o r ,m a ya l s ob ea b l et oe n h a n c ee n g r a f t m e n to f
donor cells to muscle of patients with muscular dystro-
phy. We will use the canine-to-murine and human-to-
murine xenotransplantation model, as well as the
canine-to-canine allogeneic transplant model, to test the
efficacy of this inhibitor in preclinical studies.
Conclusions
The canine-to-murine xenotransplantation model accu-
rately predicted the increase in donor cell engraftment
observed in allogeneic canine-to-canine transplantation
after treatment of donor cells with diprotin A to inhibit
CD26/DPP-IV peptidase activity. Importantly, diprotin
A treatment stimulated sustained donor cell prolifera-
tion in vivo, resulting in an increased number of fibers
expressing dystrophin, and the potential for long-term
therapeutic benefit. Furthermore, our results suggest the
potential pre-clinical utility of a human-to-mouse xeno-
transplantation model in assessing the relative efficacy
of human muscle stem cell populations.
Additional material
Additional file 1: Canine muscle cell engraftment into mouse
muscle is quantifiable and consistent. This file shows specificity of the
dystrophin and lamin A/C antibodies used, and provides quantitative
engraftment data for muscle-derived cells from additional donor canines.
Figure 7 Diprotin A enhances engraftment of donor cells in
canine allogeneic transplantation. (A) Skeletal muscle
cryosections from a chimeric cxmd canine (H376) biopsied 8, 16,
and 24 weeks after injection with 5 × 10
5 donor cells in 1.2% BaCl2,
or 5 × 10
5 donor cells treated with diprotin A in 1.2% BaCl2 were
immunostained with anti-dystrophin and fluorescently labeled
secondary antibodies. The number of fibers expressing canine
dystrophin was determined and the points represent the average
number of fibers expressing dystrophin ± SD (n = 5 cryosections
from each biopsy). (B) Skeletal muscle cryosections from a chimeric
cxmd canine (H220) biopsied 8, 16, and 24 weeks after injection
with 4 × 10
5 donor cells or 4 × 10
5 donor cells treated with
diprotin A were immunostained with anti-dystrophin and
fluorescently labeled secondary antibodies. The number of fibers
expressing canine dystrophin was determined and the points
represent the average number of fibers expressing dystrophin ± SD
(n = 5 cryosections from each biopsy).
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DMD: Duchenne muscular dystrophy; PBS: phosphate buffered saline; HSCT:
hematopoietic stem cell transplant; DPP-IV: dipeptidylpeptidase IV; SDF-1:
stromal derived factor 1; NOD/SCID: non-obese diabetic/severe combined
immunodeficiency; TA: tibialis anterior; BF: biceps femoris; FACS: fluorescence
activated cell sorting.
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